Aldeyra Therapeutics, Inc. (ALDX)

1.17 -0.04 (-2.90%) USD  |  NASDAQ  |  Sep 28, 15:05
More

Aldeyra Therapeutics Research and Development Expense (TTM) : 15.63M for June 30, 2026

Research and Development Expense (TTM) Chart

View Research and Development Expense (TTM) for ALDX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (TTM) Chart
Start Trial

Historical Research and Development Expense (TTM) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 15.63M
March 31, 2026 20.65M
December 31, 2025 25.66M
September 30, 2025 35.99M
June 30, 2025 43.00M
March 31, 2025 49.46M
December 31, 2024 48.22M
September 30, 2024 37.89M
June 30, 2024 32.41M
March 31, 2024 24.41M
December 31, 2023 29.46M
September 30, 2023 34.12M
June 30, 2023 38.70M
March 31, 2023 46.31M
December 31, 2022 47.31M
September 30, 2022 51.19M
June 30, 2022 52.54M
March 31, 2022 49.44M
December 31, 2021 44.94M
September 30, 2021 39.12M
June 30, 2021 32.36M
March 31, 2021 25.77M
December 31, 2020 24.68M
September 30, 2020 27.27M
Date Value
June 30, 2020 37.36M
March 31, 2020 43.14M
December 31, 2019 44.35M
September 30, 2019 43.29M
June 30, 2019 34.94M
March 31, 2019 31.07M
December 31, 2018 29.82M
September 30, 2018 26.82M
June 30, 2018 22.48M
March 31, 2018 19.53M
December 31, 2017 16.30M
September 30, 2017 14.20M
June 30, 2017 14.04M
March 31, 2017 13.03M
December 31, 2016 13.17M
September 30, 2016 12.84M
June 30, 2016 11.53M
March 31, 2016 9.949M
December 31, 2015 7.574M
September 30, 2015 5.866M
June 30, 2015 4.985M
March 31, 2015 4.400M
December 31, 2014 3.708M
September 30, 2014 2.704M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. 699.56M
Oncolytics Biotech, Inc. 13.11M
Sangamo Therapeutics, Inc. 113.79M
Sarepta Therapeutics, Inc. 783.60M
Anixa Biosciences, Inc. 4.828M